

# **ICH Public Meeting: ICH Japan Symposium 2012**

---

**July 25, 2012**

**Tsuda Hall, Shibuya-ku, Tokyo, Japan**

---

## **Program**

### **ICH Public Conference**

#### **Organized by the**

Japan Pharmaceutical Manufacturers Association (JPMA)  
Pharmaceutical and Medical Device Regulatory Science Society  
of Japan (PMRJ)

#### **Supported by the**

Ministry of Health, Labour and Welfare (MHLW)  
Federation of Pharmaceutical Manufacturers` Associations of  
JAPAN  
Pharmaceutical Manufacturers` Association of Tokyo  
Osaka Pharmaceutical Manufacturers Association  
Japan Pharmaceutical Association

---

**Working Language: Japanese**

**Simultaneous English-Japanese Translation: Not Available**

---

# PROGRAM

- 10:00-10:10 **Welcoming Address**  
Chair, ICH Project Committee, JPMA      Mr. Kohei Wada
- 10:10-10:35 **Recent Developments of ICH**  
International Planning Director, MHLW      Mr. Naoyuki Yasuda
- 10:35-11:00 **Overviews of ICH Topics**  
Director, Global Scientific and Regulatory Affairs, JPMA  
Dr. Kurajiro Kishi
- Topics for the Electronic Exchange of Information**  
*Session Chair: Mr. Koji Shomoto - JPMA*  
*Dr. Mihoko Okada – MHLW (KUMW)*
- 11:00-11:15 M2: Electronic Standards for the Transfer of Regulatory Information  
M2 Topic Leader, JPMA      Mr. Koji Shomoto
- 11:15-11:30 E2B (R3): Revision of the Electronic Submission  
in Individual Case Safety Reports  
E2B (R3) Rapporteur, MHLW(PMDA)      Ms. Ayumi Endo
- 11:30-11:45 M5: Data Elements and Standards for Drug Dictionaries  
M5 Topic Leader, MHLW (PMDA)      Ms. Maiko Suzuki
- 11:45-12:00 M8: Electronic Common Technical Document  
M8 Deputy Topic Leader, JPMA      Ms. Akiyo Fujikawa
- 12:00-12:15 Discussion (Questions & Answers)
- 12:15-13:10 **Lunch Break**
- Efficacy Topics**  
*Session Chair: Dr. Osamu Inagaki - JPMA*  
*Dr. Hidefumi Nakamura – MHLW (NCCHD CRC)*
- 13:10-13:25 E2C (R2): Clinical Safety Data Management; Periodic Benefit Risk  
Evaluation Report (PBRER)  
E2C (R2) Topic Leader, MHLW (PMDA)      Ms. Hazuki Takaura
- 13:25-13:40 E3 IWG: Structure and Content of Clinical Study Report: Q&A  
E3 IWG Topic Leader, MHLW (PMDA)      Dr. Kayo Shinohara
- 13:40-13:55 E14 IWG: The Clinical Evaluation of QT/QTc Interval Prolongation and  
Proarrhythmic Potential for Non-Antiarrhythmic Drugs: Q&A  
E14 IWG Topic Leader, JPMA      Dr. Maki Ito
- 13:55-14:10 Discussion (Questions & Answers)

## **Safety Topics**

*Session Chair: Dr. Kazuichi Nakamura - JPMA*

*Dr. Hiroshi Onodera- MHLW (PMDA)*

- 14:10-14:25 S1: Rodent Carcinogenicity Studies for Human Pharmaceuticals  
S1 Topic Leader, JPMA Mr. Shigeru Hisada
- 14:25-14:40 S10: Photosafety Evaluation  
S10 Rapporteur, MHLW (TMIPH) Dr. Dai Nakae
- 14:40-14:55 M3 (R2) IWG: Revision of Non-Clinical Safety Studies for the Conduct of  
Human Clinical Trials for Pharmaceuticals: Q&A  
M3 (R2) Topic Leader, JPMA Dr. Fumio Sagami
- 14:55-15:10 M7: Genotoxic Impurities  
M7 Topic Leader, JPMA Dr. Shigeki Sawada
- 15:10-15:25 Discussion (Questions & Answers)

## **15:25-15:40 Coffee Breaks**

## **Quality Topics**

*Session Chair: Dr. Tsuneo Okubo - JPMA*

*Dr. Haruhiro Okuda - MHLW (NIHS)*

- 15:40-15:55 Q3D: Guideline for Metal Impurity  
Q3D Topic Leader, JPMA Dr. Masayuki Mishima
- 15:55-16:10 Q11: Development and Manufacture of Drug Substances  
Q11 Deputy Topic Leader, MHLW (PMDA) Dr. Kazunori Takagi
- 16:10-16:20 Quality Brainstorming  
Topic Leader, MHLW (PMDA) Dr. Yoshihiro Matsuda
- 16:20-16:35 Discussion (Questions & Answers)

## **16:35-16:40 Closing Remarks**

Director, Global Scientific and Regulatory Affairs, JPMA

Dr. Kurajiro Kishi

### ***Scientific Program Committee***

<b>Mr. Naoyuki Yasuda</b>	International Planning Director, Ministry of Health, Labour and Welfare
<b>Dr. Toshiyoshi Tominaga</b>	Office Director, Office of International Program, Pharmaceuticals and Medical Devices Agency
<b>Ms. Yasuko Inokuma</b>	Deputy Director, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
<b>Dr. Jun Kitahara</b>	Division Director, Division of Regulatory Cooperation, Office of International Programs, Pharmaceuticals and Medical Devices Agency
<b>Mr. Kohei Wada</b>	Chair, ICH Project Committee, Japan Pharmaceutical Manufacturers Association (Vice President/General Manager, Global Project Management Department, R&D Division Daiichi Sankyo Co., Ltd)
<b>Dr. Kurajiro Kishi</b>	Director, Global Scientific and Regulatory Affairs, Japan Pharmaceutical Manufacturers Association

### ***Organization Committee***

<b>Mr. Shigeki Tsuda</b>	Senior Executive Director, Pharmaceutical and Medical Device Regulatory Science Society of Japan
<b>Dr. Kimiko Mogami</b>	Executive Director, Pharmaceutical and Medical Device Regulatory Science Society of Japan
<b>Mr. Kohei Wada</b>	Chair, ICH Project Committee, Japan Pharmaceutical Manufacturers Association (Vice President/General Manager, Global Project Management Department, R&D Division Daiichi Sankyo Co., Ltd)
<b>Dr. Kurajiro Kishi</b>	Director, Global Scientific and Regulatory Affairs, Japan Pharmaceutical Manufacturers Association
<b>Ms. Sayuri Masuko</b>	JPMA ICH Secretariat, Japan Pharmaceutical Manufacturers Association

***For further information, please contact JPMA ICH Coordinator:***

*Dr. Kurajiro Kishi, Tel.: +81-3-3241-0326, Fax: +81-3-3242-1767*

*E-mail:kishi@jpma.or.jp*

*JPMA postal address: Japan Pharmaceutical Manufacturers Association, Torii  
Nihonbashi Bldg., 3-4-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan*